Why the study?
Does sufficient and frequent dosing of ACE inhibitors improve clinical efficacy in patients with left ventricular dysfunction?
Does sufficient and frequent dosing of ACE inhibitors improve clinical efficacy in patients with left ventricular dysfunction?
This review highlights the importance of titrating ACE inhibitors to the higher, more frequent target doses used in clinical trials to achieve optimal benefit in left ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
May support titration to trial ACE inhibitor doses in LV dysfunction; leaves open confirmation in contemporary randomized data.
In the present review, we discuss the role of clinical dosing of angiotensin converting enzyme (ACE) inhibitors in the treatment of left ventricular dysfunction. Although the precise mechanism of action of ACE inhibitors is still unresolved, the clinical efficacy of ACE inhibitors in the treatment of left ventricular dysfunction is well established. However, it is unclear whether the doses used in clinical trials translate directly into daily practice. Several reasons may cause differences between clinical practice and controlled trials: (1) clinical trials used higher doses than in normal practice; (2) some patients may be relatively 'resistant' to ACE inhibition; and/or (3) ACE activity increases during ACE inhibitor therapy and may provide escape mechanisms when the drug regimen is not strictly adhered to. Therefore, it is of interest that recent trials suggest that only the higher doses of ACE inhibition are clinically efficacious. In conclusion, it is suggested that optimal benefit from treatment with an ACE inhibitor in patients with left ventricular dysfunction requires sufficient and frequent dosing of the ACE inhibitor, e.g., enalapril 10 mg twice daily or captopril 25 mg three times daily.
No takes yet. Share an insight, caveat, or question.
Pinto et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: